TM6SF2 Antibody, FITC conjugated

說明書

中文名稱：

TM6SF2兔多克隆抗體, FITC偶聯(lián)
貨號(hào)：

CSB-PA023622LC01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) TM6SF2 Polyclonal antibody
Uniprot No.：

Q9BZW4
基因名：

TM6SF2
別名：

TM6S2_HUMAN antibody; Tm6sf2 antibody; Transmembrane 6 superfamily member 2 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Transmembrane 6 superfamily member 2 protein (290-331AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. May function as sterol isomerase.
基因功能參考文獻(xiàn)：
1. TM6SF2 determines the risk of NASH and significant fibrosis. PMID: 29193269
2. Deleterious and protective mutations in MTTP, PNPLA3, and TM6SF2 have been found in Japanese males at risk for non-alcoholic fatty liver disease. PMID: 28950858
3. Study explored the influence of rs58542926, a missense variant of TM6SF2 involved in the regulation of lipid metabolic process, on the concentration of aminotransferases in the circulating compartment. Interestingly, the results found that the rs58542926 variant exerts a moderate but statistically significant effect on circulating level of both ALT and AST in patients with NAFLD, but not in chronic viral hepatitis. PMID: 27278285
4. hepatic synthesis of polyunsaturated fatty acid containing lipids is impaired in TM6SF2 E167K gene variant carriers. PMID: 28235613
5. association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns PMID: 28539357
6. the TM6SF2 C>T polymorphism affects nutrient oxidation, glucose homeostasis, and postprandial lipoprotein, adipokine, and GIP responses to fat ingestion independently of fasting values PMID: 28242789
7. These data demonstrate that rs58542926 (E167K) and rs187429064 (L156P) are functional variants and suggest that they influence metabolic traits through altered TM6SF2 protein stability. PMID: 28449094
8. Children carrying the T allele of the MBOAT7 polymorphism had higher plasma alanine aminotransferase than the noncarriers; children with the MBOAT7, PNPLA3, and TM6SF2 variants had the highest plasma ALT PMID: 27411039
9. carriers of the 167K allele have higher plasma alanine aminotransferase but lower plasma triglycerides and total and LDL cholesterol than the noncarriers already in childhood PMID: 26756786
10. The TM6SF2 knock-down cells secreted lipoprotein-like particles. PMID: 28434889
11. TM6SF2 association with adiposity and the risk of the nonalcoholic fatty liver disease PMID: 28436986
12. Fibrosis stages were affected by the PNPLA3 (P = 0.042) and MBOAT7 (P = 0.021) but not by the TM6SF2 polymorphism (P > 0.05). The PNPLA3, TM6SF2, and MBOAT7 variants are associated with increased liver injury. The TM6SF2 variant seems to modulate predominantly hepatic fat accumulation, whereas the MBOAT7 polymorphism is linked to fibrosis. The PNPLA3 polymorphism confers risk of both increased steatosis and fibrosis PMID: 27836992
13. The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts chronic hepatitis C and chronic hepatitis B viral load. PMID: 26822232
14. Data suggest that a polymorphism in TM6SF2 (E167K) affects cell cycle of hepatocellular carcinoma cell line and is involved in gene expression regulation. PMID: 28407767
15. In HIV/HCV coinfection the TM6SF2 E167K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype PMID: 27784963
16. The investigator looked for but could not find any affect of TM6SF2 genotype on histological features, including stage of fibrosis in NAFLD Japanese patients. PMID: 26610348
17. Expression of TM6SF2 promoted cholesterol biosynthesis in hepatocytes. PMID: 26774178
18. The TM6SF2 p.E167K variant is associated with non-alcoholic fatty liver disease. PMID: 26745555
19. In summary we found the TM6SF2 167K variant is associated with a higher prevalence of hepatic steatosis. PMID: 26520056
20. transmembrane 6 superfamily 2 C/T or T/T variants in conjunction with patatin-like phospho-lipase domain-containing protein 3 G/G variants may be potential genetic risk factors for developing HCC in alcohol-related cirrhosis. PMID: 26493626
21. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 Chronic hepatitis C. PMID: 26259026
22. This study investigates the association between TM6SF2 rs58542926 with health services utilization in a general population. TM6SF2 rs58542926 was associated with the number of outpatient visits, hospitalization, and inpatient days. PMID: 26847197
23. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: effect of Omacor administration. PMID: 26272871
24. Although the TMS6SF2 E167K variant predisposes obese children to NAFLD, there is an association between this variant and lower levels of cardiovasc risk factors: differential effects of TMS6SF2 E167K variant on liver and heart health. PMID: 25893821
25. Variants in the TM6SF2 gene is associated with alcohol-related cirrhosis. PMID: 26482880
26. The rs58542926 SNP in the TM6SF2 gene is associated with pediatric nonalcoholic fatty liver disease but may confer protection against cardiovascular risk PMID: 26457389
27. TM6SF2 polymorphism is an independent predictor of liver steatosis in patients with chronic hepatitis C. PMID: 25581573
28. in a Han Chinese population cohort, the TM6SF2 E167K allele is significantly associated with non-alcoholic fatty liver disease PMID: 25687425
29. Although the TM6SF2-rs58542926 variant confers protection against cardiovascular disease at the expense of an increased risk of nonalcoholic fatty liver, it does not explain the link between these two complex diseases. PMID: 26331730
30. TM6SF2-rs58542926 has a dual and opposite role in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver. PMID: 26331730
31. TM6SF2 expression is significantly decreased in the liver of patients with NAFLD, and rs58542926 variant might regulate liver transcript and protein expression in an allele-specific manner. PMID: 25302781
32. the E167K variant in TM6SF2 is associated with a distinct subtype of NAFLD, characterized by preserved insulin sensitivity with regard to lipolysis, hepatic glucose production and lack of hypertriglyceridemia despite a clearly increased liver fat content PMID: 25457209
33. TM6SF2 rs58542926 is associated with hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. PMID: 24978903
34. E167K variant impacts on steatosis severity and is associated with liver damage and fibrosis in patients with chronic hepatitis C PMID: 25820484
35. The TM6SF2 variant is rare in the Chinese population with non-alcoholic fatty liver disease. PMID: 24824280
36. rs58542926 is associated with nonalcoholic fatty liver disease and metabolic syndrome. PMID: 25639710
37. Carriers of the TM6SF2 E167K variant are more susceptible to progressive nonalcoholic steatohepatitis, but are protected against cardiovascular disease. PMID: 25251399
38. rs58542926 is a low-frequency variant with a modest effect on nonalcoholic fatty liver PMID: 25302781
39. TM6SF2 is a regulator of liver fat metabolism with opposing effects on the secretion of TRLs and hepatic lipid droplet content PMID: 24927523
40. The non-synonymous TM6SF2 SNP coding Glu167Lys is associated not only with presence of Non-Alcoholic Fatty Liver Disease (NAFLD) but also with the clinically relevant histological endpoint of advanced hepatic fibrosis/cirrhosis. PMID: 24978903
41. TM6SF2 activity is required for normal very-low-density lipoprotein secretion; impaired TM6SF2 function causally contributes to Nonalcoholic fatty liver disease. PMID: 24531328
42. TM6SF2 variant (Glu167Lys) influences total cholesterol levels and is associated with myocardial infarction. PMID: 24633158
顯示更多

收起更多
亞細(xì)胞定位：

Endoplasmic reticulum membrane; Multi-pass membrane protein. Endoplasmic reticulum-Golgi intermediate compartment membrane; Multi-pass membrane protein.
蛋白家族：

TM6SF family
組織特異性：

Substantial expression in liver and intestine, whereas all other tissues analyzed show low levels.
數(shù)據(jù)庫鏈接：

HGNC: 11861

OMIM: 606563

KEGG: hsa:53345

STRING: 9606.ENSP00000374014

UniGene: Hs.531624

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human